Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Halozyme Therapeutics, Inc (0J2O) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Halozyme Therapeutics, Inc $124, price $109, upside +13.6%, quality 83 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
HT
Broad data
Sep 24, 2026
Halozyme Therapeutics, Inc
0J2O · LSEUndervalued, solidQuality growthFair Value upside is positive and quality is strong.
✓Fair value $124.10 · Undervalued (+13.6%)
✓Quality 83/100
!Mixed Growth (revenue 5y +39.2 %/yr)
✓Highly profitable · 23.1% net margin (TTM)
✓generates free cash flow
✓Wide moat 99/100
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.
How to read this chart
10‑month range $61.78 – $114.02 · fair‑value band $67.50 – $161.33 · the $109.22 price screens below the $124.10 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Sep 24, 2026.
Company profile
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
Show more
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Stock analysis
Halozyme Therapeutics, Inc (0J2O) currently trades at $109.22, while our model-based Fair Value estimate is $124.10, implying the stock looks roughly 12.0% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $99.28 per share, and 4 of the 24 models we run sit above the $109.22 price.
Bear case: the Multiples group reads lowest at $25.18, and 20 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: $67.50 (bear) to $161.33 (bull), the price of $109.22 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 83/100 (high quality).
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Halozyme Therapeutics, Inc reported revenue of $1.4B in FY2025 versus $443M in FY2021, a compound +33.2%/yr. Reported net income was $317M in FY2025, compounding −5.8%/yr from FY2021.
Key figures
Market cap $13.5B · P/E ratio 0.3 · P/S ratio 0.06 · EPS (TTM) $3.00 · Net margin 22.7% · Return on equity 99.4% · Return on assets (EBIT) 23.2% · Operating margin 49.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
Fair Value models
Bear $67.50
Fair Value $124.10
Bull $161.33
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($2.27 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$73.79
$113.10
$235.69
71
EPV
$43.01
$49.65
$55.39
70
Growth DCF
$69.35
$131.16
$230.75
70
All 24 models by family
DCF Models
FCF DCF
$73.79
$113.10
$235.69
71
Owner Earnings
$43.51
$95.29
$200.00
66
5Y Revenue Exit
$35.19
$52.60
$88.42
66
5Y EBITDA Exit
$66.98
$116.88
$214.69
67
5Y P/E Exit
$46.14
$92.01
$152.82
63
10Y Revenue Exit
$46.61
$83.48
$101.46
63
10Y EBITDA Exit
$70.03
$150.38
$289.11
60
10Y P/E Exit
$55.16
$106.52
$187.03
57
Earnings-Based
Graham-Dodd
$14.97
$104.40
$146.50
61
Lynch FV
$53.93
$77.05
$100.16
59
PEG = 1.0
$53.93
$77.05
$100.16
55
EPV
$43.01
$49.65
$55.39
70
Multiples
P/E Multiple
$33.02
$44.03
$55.03
63
P/S Multiple
$18.19
$24.26
$30.32
58
P/B Multiple
$0.7600
$1.02
$1.27
55
EV/EBIT
$77.48
$103.00
$128.52
63
EV/EBITDA
$62.18
$82.60
$103.02
64
EV/Revenue
$17.91
$25.18
$32.46
51
Asset-Based
NCAV (Graham)
$0.1700
$0.2300
$0.3400
51
Growth DCF
Growth DCF
$69.35
$131.16
$230.75
70
Rev-Margin DCF
$38.29
$60.16
$106.51
65
Economic Profit
Residual Income
$1.28
$2.34
$7.20
56
ROIC Compounder
$43.01
$49.65
$55.39
68
Growth Earnings
Growth-Adj P/E
$69.50
$99.28
$129.07
65
Notify me when 0J2O reaches fair value
Put 0J2O on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
83/100
Of which business quality 77 · Market factors (momentum, volatility) 86
Profitability
74
Margins and returns on capital today
Quality Growth
56
Are margins and returns improving?
Cashflow
100
Earnings quality: real cash, not paper profit
Fin. Strength
54
Balance sheet, leverage, solvency risk
Investment
77
Disciplined investing over empire-building
Low Volatility
61
Calm price path (market factor)
Momentum
98
Price trend over the last 3–12 months (market factor)
52W Momentum
95
Distance to the 52-week high (market factor)
Net Issuance
100
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
92/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+37.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.2%
Start year 2020 (pandemic). Over 10 years: +26.3% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+57.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+6.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.9%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.54% → 58%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+10.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+13.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +8.1% a year for the price and +11.1% for the forecasts.
Forecast 2026 (sales)+26.9%
Forecast 2027 (sales)+12.8%
Projected 2028 (sales)+11.4%
Projected 2029 (sales)+10.1%
Projected 2030 (sales)+8.7%
Watch 0J2O, get fair value alerts →
Compare Halozyme Therapeutics, Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Context: sector, industry, market
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: UK Stocks
- Valuation of the UK market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Explore undervalued stocks
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Halozyme Therapeutics, Inc (0J2O) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $124.10 versus a price of $109.22, about +14% upside (undervalued).
What is the fair value of 0J2O?
Our model-based fair value for Halozyme Therapeutics, Inc is $124.10 (as of Sep 24, 2026), built from audited fundamentals. The current price: $109.22.
What is the quality score of 0J2O?
Halozyme Therapeutics, Inc has a Quality Score of 83/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Halozyme Therapeutics, Inc (0J2O)?
Our model-based price target is the fair value of $124.10 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $67.50, optimistic scenario $161.33. It is a calculation from audited fundamentals, not an analyst target.
What is the Halozyme Therapeutics, Inc stock forecast for 2026?
Our models put fair value at $124.10, about +14% upside versus a price of $109.22 (undervalued). Cautious scenario $67.50, optimistic scenario $161.33. The calculation is refreshed regularly with new filings.
What is the revenue of Halozyme Therapeutics, Inc (0J2O)?
Halozyme Therapeutics, Inc reported trailing-twelve-month revenue of about $1.5B (latest available figure, as of Sep 24, 2026).
What growth is priced into Halozyme Therapeutics, Inc (0J2O)?
For today's price to be fair in a discounted-cash-flow model, Halozyme Therapeutics, Inc would have to grow free cash flow by +10.6 % per year for five years (discount rate 9.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +39.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 0J2O use?
Our models discount Halozyme Therapeutics, Inc at 9.9 %: a base by market capitalisation (unknown), damped by beta 0.84, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Halozyme Therapeutics, Inc that is +10.6 % per year a year over ten years, using the same discount rate (9.9 %) and the same formula as our fair value.
How much growth has Halozyme Therapeutics, Inc (0J2O) delivered so far?
Over the past 5 years revenue at Halozyme Therapeutics, Inc grew +39.2 % a year. The price currently implies +10.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
What is the free cash flow yield of Halozyme Therapeutics, Inc (0J2O)?
The free-cash-flow yield on the price is 4.76 %: that much free cash flow Halozyme Therapeutics, Inc produces per unit of market value. When it exceeds the discount rate of our models (9.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Halozyme Therapeutics, Inc (0J2O)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Halozyme Therapeutics, Inc it is $124.10 per share (as of Sep 24, 2026), against a price of $109.22. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Halozyme Therapeutics, Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0J2O trades below its calculated fair value: price $109.22, fair value $124.10, a gap of about +14% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0J2O?
No. The price is what the market pays today ($109.22); the fair value is what the company's own numbers justify ($124.10). For Halozyme Therapeutics, Inc the two are $14.88 per share apart. That gap is exactly why we show both numbers side by side.
How much is Halozyme Therapeutics, Inc worth?
The market values Halozyme Therapeutics, Inc at about $13.5B (market capitalisation, as of Sep 24, 2026). Per share that is $109.22; our models calculate a fair value of $124.10 per share.
What do the bullish and bearish scenarios say about 0J2O?
Our models span a range for Halozyme Therapeutics, Inc: cautious scenario $67.50, base $124.10, optimistic $161.33 per share (as of Sep 24, 2026, price $109.22). The range comes from different growth and margin assumptions, not from analyst opinions.
Is Halozyme Therapeutics, Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $109.22, calculated fair value $124.10 (+14%), Quality Score 83/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0J2O calculated?
We run Halozyme Therapeutics, Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $124.10, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Halozyme Therapeutics, Inc currently trades 12 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Halozyme Therapeutics, Inc (0J2O)?
The closing price on Oct 2, 2026 was $109.22. Our model-based fair value is $124.10, about +14% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Halozyme Therapeutics, Inc right now?
A fairly wide model range ($67.50 to $161.33) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Halozyme Therapeutics, Inc
How large is the market capitalisation of Halozyme Therapeutics, Inc (0J2O)?
The market capitalisation of Halozyme Therapeutics, Inc is $13.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Halozyme Therapeutics, Inc (0J2O)?
The price-to-earnings ratio of Halozyme Therapeutics, Inc is 0.3 (as of Jul 24, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Halozyme Therapeutics, Inc (0J2O)?
The price-to-sales ratio of Halozyme Therapeutics, Inc is 0.06 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Halozyme Therapeutics, Inc (0J2O)?
Earnings per share at Halozyme Therapeutics, Inc are $3.00 (price ÷ EPS = P/E 0.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Halozyme Therapeutics, Inc (0J2O)?
The net margin of Halozyme Therapeutics, Inc is 22.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Halozyme Therapeutics, Inc (0J2O)?
The return on equity (ROE) of Halozyme Therapeutics, Inc is 99.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Halozyme Therapeutics, Inc (0J2O)?
On an EBIT basis the return on assets of Halozyme Therapeutics, Inc is 23.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Halozyme Therapeutics, Inc (0J2O)?
The operating margin of Halozyme Therapeutics, Inc is 49.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Halozyme Therapeutics, Inc (0J2O)?
Revenue at Halozyme Therapeutics, Inc is growing +42.2% versus a year earlier (3y avg +28.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Halozyme Therapeutics, Inc (0J2O)?
Earnings per share at Halozyme Therapeutics, Inc are growing +31.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Halozyme Therapeutics, Inc (0J2O) carry?
The net debt of Halozyme Therapeutics, Inc is $2.1B (fiscal year 2025, ≈ 3.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
Open the live analysis →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.